Company structure
The AdnaGen AG is a stock holding company whereby the shares are not yet traded in public.

Currently, the shareholder structure is composed as follows:
- OncoVista Inc., San Antonio, TX, USA
- Founders
- Private group of investors
- Rose Nominees Ltd., St. Peter Port, UK

Financing
AdnaGen was founded in 1999 first as a GmbH (limited company) and financed by Venture Capital as well as funds from the tbg (Technologiebeteiligungsgesellschaft, a Government-led organization) in the form of a "silent" participation". The tbg is a subsidiary of the government-owned 'Deutsche Ausgleichsbank' with emphasis on supplementary financing of start-up companies provided there is a lead investor

Furthermore, AdnaGen received governmental support in the form of R&D grants for the product area Rare Cell Detection & Analysis (tumor and prenatal diagnostics).

Investor relations contact
For any further information and questions related to an investment into AdnaGen please do not hesitate to contact Alexander Weis, Chief Executive Officer:

Phone: ++49 (0) 511 725 950-50
Fax: ++49 (0) 511 725 950-40
e-mail: aw@adnagen.com